AbbVie Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ABBV New York 2834 https://www.abbvie.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AbbVie Inc

Buy AbbVie Stock Because You ‘Can’t Ignore’ How Cheap It Is - Aug 20th, 2019 9:06 am
Here's Why Allergan is Outperforming Its Industry Of Late - Aug 20th, 2019 7:44 am
AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira - Aug 20th, 2019 4:00 am
High-Dividend Stocks on Historic Discount as Yields Plunge, says Goldman - Aug 20th, 2019 3:48 am
Stocks To Buy: Is It Time To Buy Or Sell These Large-Cap Stocks? - Aug 19th, 2019 9:49 am
AbbVie Rises 3% - Aug 19th, 2019 6:58 am
AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA - Aug 19th, 2019 6:04 am
5 Biggest New Drug Approvals Potentially on the Way in 2019 - Aug 19th, 2019 4:00 am
How AbbVie Plans To Take On Pfizer, Lilly — And Kick Its Humira Habit - Aug 16th, 2019 2:25 pm
How Merck Could Ride 'The Keytruda Wave' To Dominate These Rivals - Aug 16th, 2019 2:20 pm
FDA approves AbbVie's Rinvoq to treat moderate-to-severe RA - Aug 16th, 2019 12:06 pm
AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should You Buy It? - Aug 16th, 2019 11:35 am
UPDATE 2-AbbVie prices new rheumatoid arthritis drug at $59,000/yr - Aug 16th, 2019 10:49 am
AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis - Aug 16th, 2019 10:43 am
Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe - Aug 16th, 2019 7:19 am
The Top Pharma Stocks for 2019 - Aug 15th, 2019 1:36 pm
13 High-Yield Dividend Stocks to Watch - Aug 15th, 2019 11:49 am
5 Top Cancer-Fighting Stocks to Buy Now - Aug 14th, 2019 7:00 pm
How Tesla has Become Most Profitable Short Bet at $2.75 Billion - Aug 14th, 2019 3:17 pm
Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study - Aug 14th, 2019 7:24 am